Abstract
One therapeutic concept in chronic myeloid leukemia (CML) assumes that a reduction of clonal genetically unstable cells also reduces the rate of secondary genetic changes and thereby postpones blast crisis. According to this concept, the degree of reduction of tumor burden should correlate with a prolongation of survival. The recent literature, in particular on controlled studies of IFN, hydroxyurea or intensive chemotherapy is reviewed and analyzed with regards to this concept. In chronic phase CML, intensity of treatment as determined by the degrees of WBC suppression, and, more recently, of cytogenetic remission, as measures of the reduction of tumor burden appear to correlate directly with survival. The superiority of a therapeutic regimen in chronic phase CML seems to primarily depend on whether its pharmacology permits a sufficiently high dosage to achieve the necessary reduction of tumor burden. The concept underlies present strategies that try to prolong survival in CML by IFN alone or in combination with intensive chemotherapy, by hydroxyurea, alone or in combination with IFN, and by high-dose chemotherapy followed by autografting.
References
Jun 30, 1979·Lancet·J C SharpY Williams
Jan 1, 1979·Leukemia Research·I BrodskyJ F Conroy
Sep 15, 1991·Cancer·H M KantarjianE J Freireich
Apr 1, 1991·Annals of Internal Medicine·M TalpazJ U Gutterman
Jan 1, 1987·Acta Haematologica·H M KantarjianE J Freireich
Apr 24, 1986·The New England Journal of Medicine·M TalpazJ U Gutterman
Jul 15, 1987·Klinische Wochenschrift·L Müller, R Hehlmann
Mar 1, 1987·Controlled Clinical Trials·P K Andersen
Feb 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianE J Freireich
Apr 1, 1972·Cancer·B J Kennedy
Jan 1, 1984·Statistics in Medicine·R Simon, R W Makuch
May 1, 1983·American Journal of Physical Anthropology·C J UtermohleG M Heathcote
Jun 1, 1982·American Journal of Clinical Oncology·D RushingB J Kennedy
Nov 1, 1982·Cancer·R W BolinR F Hamman
Mar 1, 1995·British Journal of Haematology·A M CarellaF Benvenuto
Jun 3, 1995·Lancet·N C AllanP C Shepherd
Feb 15, 1995·Annals of Internal Medicine·H M KantarjianM Talpaz
Oct 1, 1993·Stem Cells·B SimonssonC Malm
Jun 11, 1994·Lancet·P B McGlaveD Aeppli
Jan 1, 1994·British Journal of Haematology·C HoyleJ Goldman
Mar 24, 1994·The New England Journal of Medicine·UNKNOWN Italian Cooperative Study Group on Chronic Myeloid LeukemiaMauro Fiacchini
Mar 24, 1994·The New England Journal of Medicine·J O Armitage
Aug 1, 1993·Annals of Hematology·M GriesshammerH Heimpel
Mar 4, 1993·The New England Journal of Medicine·N A KernanJ McCullough
Mar 1, 1993·British Journal of Haematology·O KlokeR Becher
Citations
Apr 29, 2005·Leukemia·M GiehlW Seifarth
Jan 19, 2002·Journal of Hematotherapy & Stem Cell Research·J ThieleH E Schaefer
Aug 3, 2002·Leukemia & Lymphoma·Hana BruchovaRadim Brdicka
Jul 8, 2000·American Journal of Clinical Pathology·J ThieleH E Schaefer
May 4, 2002·Best Practice & Research. Clinical Haematology·Andreas Hochhaus
Jun 6, 1998·Blood Cells, Molecules & Diseases·O M TrappP E Petrides
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rüdiger HehlmannSusanne Saussele
Jun 1, 2002·Leukemia·J Giron-MichelP Eid
Jun 24, 2000·Leukemia·A HochhausN C Cross
Sep 13, 2003·Leukemia·P PaschkaA Hochhaus
Aug 24, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·J ThieleH E Schaefer
Jun 19, 2007·Oncology Nursing Forum·Roxanna L Gapstur
Jun 2, 2012·Blood·Rüdiger Hehlmann